Analysed IMMIX BIOPHARMA INC (IMMX:NASDAQ) News Sources
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
27-05-2026
yahoo.com
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
18-06-2026
yahoo.com
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
29-09-2026
yahoo.com
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
29-09-2026
stocktwits.com
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
30-09-2026
yahoo.com
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
05-10-2026
marketbeat.com
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
05-10-2026
yahoo.com
What is the current price of IMMIX BIOPHARMA INC (IMMX:NASDAQ)?
The current price of IMMIX BIOPHARMA INC (IMMX:NASDAQ) is $8.01.
IMMIX BIOPHARMA INC (IMMX:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMIX BIOPHARMA INC (IMMX:NASDAQ) since the previous trading day is $-0.05.
IMMIX BIOPHARMA INC (IMMX:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMIX BIOPHARMA INC (IMMX:NASDAQ) since the previous trading day is -0.6203%.
What is the most recent average sentiment score for IMMIX BIOPHARMA INC (IMMX:NASDAQ)?
The most recent average sentiment score for IMMIX BIOPHARMA INC (IMMX:NASDAQ) is 40 out of 100.
What is the most recent average sentiment for IMMIX BIOPHARMA INC (IMMX:NASDAQ)?
The most recent sentiment for IMMIX BIOPHARMA INC (IMMX:NASDAQ) is .
SEC-8K** Filing Available For IMMIX BIOPHARMA INC (IMMX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.